Defaults for orders not otherwise specified below:
- Interval: Induction (Ulcerative Colitis) week 0, week 2, then Every 28 days
- Interval: Every 28 days

Duration:
- Until date: __________
- 1 year
- # of Treatments

Anticipated Infusion Date: __________ ICD 10 Code with Description: __________

Height: ______(cm) Weight: ______(kg) Allergies: __________

Provider Specialty
- Allergy/Immunology
- Cardiology
- Gastroenterology
- Genetics

Site of Service
- SH Gerber
- SH Lemmen Holton (GR)
- SH Pennock
- SH United Memorial
- SH Helen DeVos (GR)
- SH Ludington
- SH Reed City
- SH Zeeland

Appointment Requests
- Infusion Appointment Request
- Status: Future, Expected: S, Expires: S+366, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after injection and possible labs

Safety Parameters and Special Instructions
- ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 4
- GOLIMUMAB (SIMPONI):
  - An FDA-approved patient medication guide, which is available with the product information and as follows, should be dispensed with this medication
  - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125289s135lbl.pdf
  - Tuberculosis surveillance and management: Screen and treat latent infection prior to starting therapy.
  - Hepatitis B surveillance and management: Screen prior to initiating therapy. Refer to specialist as warranted by serology.
  - TB skin test, hepatitis B surface antigen (HBsAg) test, liver function test (LFT), complete blood count (CBC), up-to-date vaccinations, risk assessment for cancer, and pregnancy testing. Monitor for signs of tuberculosis throughout therapy. Do not initiate therapy if active infection is present. Monitor closely for signs and symptoms of infection. Monitor for signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss). Identify history of latex or polysorbate 80 allergy; some dosage containers may contain these agents. Monitor LFTs, CBC at regular intervals during treatment.
  - If self-injected, teach patient appropriate injection technique and syringe/needle disposal.

- ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 4
- HEPATITIS B VIRUS SURVEILLANCE AND MAINTENANCE RECOMMENDATIONS: Screen prior to treatment. Refer to specialist as warranted by serology.

- ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 5
- TUBERCULOSIS SURVEILLANCE AND MANAGEMENT RECOMMENDATIONS: Screen prior to treatment. Treat latent infection prior to starting therapy.

CONTINUED ON PAGE 2 ➔
**GOLIMUMAB (SIMONI), SUBCUTANEOUS - ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED)**

### Labs

<table>
<thead>
<tr>
<th>Test</th>
<th>Interval</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete Blood Count w/Differential</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic Function Panel (Liver Panel)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B Surface Antigen Level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B Core Total Antibody Level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Labs:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Every ___ days
- Until date: ______
- Once
- 1 year
- ______ # of Treatments

☐ **Arrange For Patient To Have Id Tb Skin Test Administered And Read Or Serum Tb Screening Lab Prior To Therapy Or Annually**

- ONC PROVIDER REMINDER 28
  - Once
  - 1 treatment
  - Arrange for patient to have intradermal TB skin test (tuberculin PPD) screening performed and read prior to initiating therapy and annually.

- TB Screen (Quantiferon Gold)
  - Once
  - 1 treatment

### Nursing Orders

- ONC NURSING COMMUNICATION 200
  - May Initiate IV Catheter Patency Adult Protocol.

### Treatment Parameters

- ONC MONITORING AND HOLD PARAMETERS 3
  - May proceed with treatment if hepatitis B core antibody and surface antigen labs have been resulted prior to the first dose, and the results are negative.

- ONC MONITORING AND HOLD PARAMETERS 4
  - May proceed with treatment if tuberculosis screening test with either TB Screen blood test (QuantiFERON® Gold Plus) or TB skin test have been resulted prior to first dose and the results are negative.

### Medications

- **Golimumab (simponi) Autoinjector Or Prefilled Syringe**
  - Rotate injection sites and avoid injecting into tender, red, scaly, hard, or bruised skin, or areas with scars or stretch marks. If multiple injections are required for a single dose, administer at different sites on body
  - Hold autoinjector firmly against skin and inject subcutaneously into thigh, lower abdomen, or upper arm. A loud click is heard when injection has begun. Continue to hold autoinjector against skin until second click is heard (may take 3 to 15 seconds).

  Ankylosing spondylitis, Psoriatic arthritis, or Rheumatoid arthritis:
  - 50 mg

  Induction for Ulcerative Colitis:
  - 200 mg, Subcutaneous at week 0
  - 100 mg, Subcutaneous at week 2

  Maintenance for Ulcerative Colitis:
  - 100 mg, Subcutaneous

### Telephone order/Verbal order documented and read-back completed. Practitioner’s initials ____________

**NOTE:** Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.